CPPR Loses a Legend

Posted on by

Feb 27, 2018 – University of Connecticut

2/27/2018

CPPR is greatly saddened by the untimely passing of Professor Michael Pikal, who through the years, served as the CPPR Site Director at UConn until his recent retirement. Throughout his prolific career, first in industry and later in academia, Dr. Pikal has been a pioneer in the pharmaceutical sciences. His numerous seminal contributions have helped shape the area of drug development in a profound manner. Through his scientific breakthroughs and his mentorship of many of the leading scientists in the field, Mike provided a legacy of excellence in his endeavors that will be treasured by pharmaceutical scientists everywhere throughout the years.  We count ourselves as being fortunate that we have gotten to share his input and have gotten to witness the tremendous care he brought forth to research, mentorship, and citizenship to those of us lucky enough to have collaborated with him.
Read more at UConn Today

 

October 2017 CPPR Meeting

Posted on by

Congratulations CPPR IAB member, Sajal Patel of Medimmune, on the publishing of best practices paper,

“Lyophilized Drug Product Cake Appearance: What is Acceptable?”

UPR grad students win awards

  • First Place, Excipient Fest Student Poster: Marlene Rodriguez, E.S. Ghaly. (2015). Preparation and Characterization of Ketoprofen Nanostructured Lipid Carrier by High Pressure Microfluidizer. International Excipient Fest, San Juan, PR, April 28-29, 2015.
  • Second Place Award for Applied Basic Science Poster Award: Maria Del Mar, E.S. Ghaly. (2015) Compaction Characterization and Physico-Chemical Properties of of Anti-histaminic Tablets Using Avicel HFE. Annual Research and Education Forum, Medical Sciences Campus, Univ. of Puerto Rico, San Juan, PR.
  • Second Place Award for Int’l IPEC Meeting, Student Poster: I. Moreno, E.S. Ghaly. (2014). Mechanical Properties and Physical Characterization of New Co-Processed Pharmaceutical Excipient Using Acetaminophen as an Active Ingredient and Direct Compression. International IPEC Meeting, Raleigh, North Carolina.
  • IPEC Travel Award to 2014 AAPS: I. Moreno, E.S. Ghaly. (2014). Characterization and Comparison between Novel Co-processed Excipients Avicel DG and Avicel HFE Using Acetaminophen Compacted by Direct Compression. 2014 AAPS Meeting, San Diego, CA, November 2-6, 2014.

UMN grad student receives two awards

UMN graduate student Mehak Mehta (Suryanarayanan lab) received the following awards:

  • 2014 AAPS Graduate Student Symposium award in Physical Pharmacy & Biopharmaceutics section, for her podium presentation “Influence of polymer properties on the molecular mobility in the glassy state” at the AAPS meeting held in San Diego in November.
  • 2014 AAPS Best Poster Award in Analysis & Pharmaceutical Quality (APQ) section, for her poster presentation “Dielectric spectroscopy: a technique to measure structural relaxation in glassy pharmaceuticals”.

 

Pinal elected to Purdue Innovator Hall of Fame
Dr. Rodolfo Pinal has been elected to the Purdue University Innovator Hall of Fame. The Innovator Hall of Fame recognizes Purdue faculty members who have developed new technologies and founded companies to bring their ideas to market. Dr. Pinal has been recognized for developing new technologies for precision compounding of drugs, commercialized through BioKorf, LLC.

CPPR Center Director’s startup develops pre-fab drug dosages
CPPR Center Director Dr. Rodolfo Pinal’s Biokorf, LLC, is creating prefabricated drug dosages that could be used by compounding pharmacists to support patient-centered, precision medicine (PCPM). The company’s technology makes pharmaceutical dosage forms in modular form from prefabricated components. The “pills” are patient-tailored in size and shape, with the precise dose and drug release characteristics that the physician prescribes for the individual patient. The Purdue Office of Technology Commercialization and Purdue Foundry have supported Biokorf officials throughout the process to translate the Purdue technology into a startup.